C urrent opinion suggests that gene therapy may hold great promise for treatment of cardiovascular diseases that lead to chronic heart failure. The assimilation of rapid advances in mouse genetics into the realm of cardiovascular research has provided pharmacologists and physiologists a tremendous range of new opportunities to unravel the molecular secrets that govern cardiovascular structure and function in health and disease. Several lines of transgenic mice have been generated to target key proteins that govern transmembrane signal transduction or modulate the contractile properties of myocardial cell. [1] [2] [3] [4] [5] [6] [7] [8] [9] One such model that has drawn substantial attention is a transgenic mouse model overexpressing the human ␤ 2 -adrenergic receptor (␤ 2 AR) in a cardiac specific manner (TG4). In this model, while baseline myocardial contractility is successfully enhanced relative to wild-type (WT) littermates, 1 cardiac responsiveness to an acute administration of the ␤-adrenergic receptor (␤AR) agonist isoproterenol (ISO) is totally lacking both in vivo and in isolated atria. 1, 7 These observations have led to a conclusion that ␤-adrenergic modulation in the TG4 mouse heart is saturated in the basal state because of a greater number of ␤ 2 ARs in the spontaneous active state (R* state) in the absence of agonists. 1, 7 Because recent studies in other mammalian species have shown that physiological responses and signal transduction mechanisms of ␤ 2 AR subtype stimulation are distinctly dif-ferent from those of ␤ 1 -adrenergic receptor (␤ 1 AR) stimulation, 10 -15 it is essential to characterize the individual ␤AR subtypes in murine heart for optimal genetic manipulation of their signaling pathways. However, a close inspection of the studies in murine models to date 1-3,6 -8 surprisingly reveals that although the contractile effects of mixed ␤AR or ␤ 1 AR stimulation have been characterized, the functionality of the ␤ 2 AR subtype at the cellular level has been ignored. In fact, whether ␤ 2 AR agonists can elicit a contractile response in murine myocardium has been a matter of debate. Specifically, in WT mice, the mixed ␤AR agonist ISO in the presence of the ␤ 1 AR antagonist CGP 20712A (CGP) has virtually no positive inotropic effect. 7 In addition, in ␤ 1 AR knockout mice, the mixed ␤AR agonist ISO fails to increase cardiac contractility. 9 Thus, it is possible that an inability of ␤ 2 AR stimulation by agonists to increase contractility in mouse heart per se masquerades as the observed "saturation" of ␤ 2 -adrenergic signaling in the TG4 mouse.
Our previous studies have shown that in native rat cardiac myocytes, pertussis toxin (PTX) pretreatment selectively potentiates the positive inotropic effect of ␤ 2 AR but not ␤ 1 AR stimulation, suggesting that ␤ 2 AR dually couples to G s and to PTX-sensitive inhibitory G proteins. 10 If the coupling of ␤ 2 AR-G i protein in murine heart were highly efficient, it might be expected to completely negate the G s -mediated positive inotropic effect. Thus, a strong coupling of ␤ 2 AR to G i proteins in murine heart may explain the apparent and mysterious loss of ␤ 2 AR contractile response in murine myocardium.
The present study was undertaken to characterize the effects of agonist-induced ␤ 2 AR subtype stimulation on contraction, [Ca 2ϩ ] i transient, L-type Ca 2ϩ currents (I Ca ), and activation of G proteins in both TG4 and WT ventricular myocytes. Surprisingly, ␤ 2 AR stimulation by ISO plus the ␤ 1 AR antagonist CGP or by zinterol was not able to enhance the contraction amplitude in either WT or TG4 myocytes. An analysis of the G protein activation profile indicated that ␤ 2 AR stimulation in both WT and TG4 mice activated PTX-sensitive G proteins (G i2 and G i3 ) in addition to G s . Pretreatment of myocytes with PTX rescued potent contractile, [Ca 2ϩ ] i , and I Ca responses to ␤ 2 AR agonists in WT as well as TG4 heart cells. These results indicate that in mouse ventricular myocytes, at normal or overexpressed receptor density, an activation of ␤ 2 AR-coupled G i proteins prevents the positive inotropic effect of agonist-induced ␤ 2 AR stimulation.
Materials and Methods

Measurements of Cell Contraction and [Ca 2؉ ] i Transient
Mouse ventricular myocytes were isolated from hearts of 2-to 3-month-old male transgenic mice overexpressing human ␤ 2 AR (TG4) and WT littermates via a modified enzymatic technique. 8 Cells were then perfused with HEPES buffer solution consisting of (in mmol/L) CaCl 2 1.0, NaCl 137, KCl 5, dextrose 15, MgSO 4 1.3, NaH 2 PO 4 1.2, and HEPES 20 (pH 7.4) and were electrically stimulated at 0.5 Hz at 23°C. Cell length was monitored from the brightfield image of the cell by an optical edge-tracking method using a photodiode array (Reticon Model 1024 SAQ) with a 3-ms time resolution. Cell contraction was indexed by the percent reduction of cell length after electrical stimulation. In some experiments, cells were loaded with the fluorescent Ca 2ϩ indicator Fluo-3 by incubation in 10 mol/L Fluo-3 AM (Molecular Probes) for 10 minutes followed by a 20-minute wash. 16 A laser scanning confocal microscope (Zeiss LSM410) was used to acquire fluorescence images every 2.09 ms along a line focused 5 to 10 m into the cell. Both the Ca 2ϩ signal and cell contraction were directly measured from the line-scan images using IDL (Research System) software. Criteria for viable mouse myocytes have been described in our previous study 8 and include (1) a rod shape, (2) clearly defined sarcomeric striations, (3) a clear negative staircase after a rest period of Ϸ1.0 minute, and (4) a stable steady-state contraction amplitude for at least 5 minutes before drug administration.
I Ca Measurements
I Ca was measured via the whole-cell patch-clamp technique with the use of an Axopatch 1D amplifier (Axon Instruments Ltd). The resistance of electrode pipettes fabricated from the glass capillary tube (World Precision Instruments, Inc) ranged between 1 and 2 M⍀. To selectively examine I Ca , cells were voltage-clamped at Ϫ40 mV to inactivate the Na ϩ current and T-type Ca 2ϩ current. The K ϩ currents were inhibited by the appropriate blockers in the pipette solution containing (in mmol/L) CsCl 100, TEACl 20, NaCl 10, HEPES 10, MgATP 5, and EGTA 5; the pH was adjusted to 7.2 with CsOH. In some experiments, Rp-cAMPS (100 mol/L), an inhibitory cAMP analog, was included in the patch pipette solution and dialyzed into the cell for more than 10 minutes, as previously described. 11 The superfusion solution was the same as that used for cell length and [Ca 2ϩ ] i transient measurements. I Ca was elicited from a depolarization from Ϫ40 to 0 mV and measured as the difference between the peak inward current and the current at the end of a 300-ms pulse.
Photolabeling of Membrane Proteins
Cardiac membranes were prepared by homogenizing WT and ␤ 2 AR overexpressing transgenic mouse (TG4) ventricles in ice-cold lysis buffer (20 mmol/L Tris-HCl [pH 7.4], 250 mmol/L sucrose, 1 mmol/L EDTA, 10 g/mL aprotinin, 10 g/mL leupeptin, and 0.1 mmol/L PMSF). The samples were centrifuged at 10 000g for 10 minutes at 4°C. The supernatant was centrifuged at 100 000g for 2 hours at 4°C. The pellet was resuspended up to a final protein concentration of 4.5 to 5 mg/mL in a buffer containing 20 mmol/L Tris-HCl (pH 7.4) and 1 mmol/L EDTA. Membranes were aliquoted and stored at Ϫ80°C.
[␥-32 P]GTP-azidoanilide ([␥-32 P]GTP-AzA) was synthesized and purified according to the procedure described previously 17 with some modifications. Briefly, 100 L of 30 mg/mL 1-ethyl-3-(3-dimethylaminopropyl)carbodiide (N-DEC) (Fluka, Buchs, Switzerland) solution in 0.15 mol/L MES (pH 5.5) and 2 to 3 mCi of lyophilized [␥-
32 P]-GTP were mixed for 10 minutes at room temperature. Then 50 L of 4-azidoanilide (40 mg/mL in 1,4-dioxane) was added to this mixture and kept at 25°C to 28°C for 3 hours with constant mixing. The synthesized [␥-
32 P]GTP-AzA was purified on a C-18 Sep-Pak Cartridge (Waters) and dried on a Speed-Vac Centrifuge. The purity of the final product was Ͼ90%, checked by thin-layer chromatography on PEI cellulose with 1 mol/L LiCl. The dried [␥-
32 P]GTP-AzA was stored at Ϫ25°C. All synthesis procedures were performed in a dark room with red light illumination.
Membrane proteins (40 to 50 g) were preincubated at 25°C for 10 minutes in 20 mmol/L Tris-HCl (pH 7.5), 50 mmol/L NaCH 3 CO 2 , 0.2 mmol/L EGTA, 1.0 mmol/L benzamidine, 2 mmol/L Mg Cl 2 , 1.0 mmol/L EDTA, and 50 mol/L GDP to load G protein ␣ subunits. ␤AR agonists or antagonists and 5 to 10 Ci of [␥- 32 P]GTP-Aza were then added to the samples and incubated for 4 minutes. The reaction was terminated by putting the samples on ice. All the subsequent procedures were performed at 4°C. After centrifugation (14 000g for 10 minutes), membrane pellets were carefully resuspended in 50 L of ice-cold buffer (20 mmol/L Tris-HCl [pH 7.4], 1 mmol/L EDTA, and 1 mmol/L dithiothreitol), transferred to individual dimples in aluminum foil, and irradiated with a UV lamp (254 nm, 100 W) for 10 minutes at a distance of 10 cm. The irradiated samples were centrifuged at 14 000g for 30 minutes.
Immunoprecipitation of G Protein ␣ Subunits
Immunoprecipitation of G protein ␣ subunits was performed as previously described. 18 Pellets of photolabeled membranes were solubilized in 40 L of 2% SDS (wt/vol) at room temperature. Precipitation buffer (103 L) containing 1% (wt/vol) Triton X-100, 1% (wt/vol) deoxycholate, 0.5% (wt/vol) SDS, 150 mmol/L NaCl, 1 mmol/L dithiothreitol, 1 mmol/L EDTA, 0.2 mmol/L PMSF, 10 g/mL aprotinin, and 10 mmol/L Tris-Cl (pH 7.4) was added, and the solubilized membranes were centrifuged at 14 000g for 5 minutes at 4°C. Antisera (5 to 20 L) was added to the supernatant. The samples were incubated overnight at 4°C under constant rotation. After adding washed protein A Sepharose beads, the samples were centrifuged at 14 000g for 5 minutes and washed with buffer A ( After a 15-minute incubation at room temperature, the samples were boiled for 10 minutes and centrifuged at 14 000g for 5 minutes. Thereafter, 20 L of supernatants was subjected to SDS-PAGE electrophoresis according to Laemmli. 19 The separating gel contained 9% acrylamide and 6 mol/L urea. Gels were stained with Coomassie blue. Photolabeled proteins were visualized by autoradiography.
PTX Treatment
For contraction, [Ca 2ϩ ] i transient, and I Ca measurements, aliquots of cells were incubated with PTX (1.5 g/mL at 37°C for at least 3 hours), as previously described. 10 PTX-treated cells were compared with nontreated control myocytes from the same heart that had been kept at 37°C in the absence of PTX for an equal time. After PTX treatment, both PTX-treated and nontreated cells were kept at room temperature for the rest of the experimental day (Ϸ6 to 8 hours). For biochemical measurements, mice were injected with PTX (150 g/kg IP) 24 hours before the isolation of the hearts. 20 
Materials
CGP was kindly supplied by Ciba-Geigy Corp, Basel, Switzerland; ICI 118,551 (ICI) was kindly supplied by Imperial Chemical Industries, London, UK; and zinterol was kindly supplied by Bristol-Myers, Evansville, Ind. Antibodies recognizing the ␣ subunits of G s and G i2 were obtained from Du Pont New England Nuclear (Wilmington, Del). The antibody recognizing the ␣ subunits of G i3 was obtained from Santa Cruz Biotechnology, Calif. In our experiments, the antibodies against G i3 (from Santa Cruz) dominantly react with G i3 , because in most experiments, the molecular weight (MW) of the G i3 antibody-precipitated proteins is slightly greater than that precipitated by the G i2 antibodies, as expected. However, these antibodies may also slightly cross-react with G i2 . In some experiments, double bands are visible, but the lower MW band, which has the same MW as that of the proteins precipitated by G i2 antibodies ( Figure 8C and 8D), is always much lighter. In addition, the G i2 antibody-precipitated proteins are mainly G i2 , even though this antibody may cross-react weakly with G i1 . The reason for this is that in our preliminary experiments, we have found that the abundance of G i1 in murine myocardium is much lower than that of G i2 and G i3 and is difficult to detect by Western analysis (data not shown). Control peptides of the G ␣i3 antibody were obtained from Santa Cruz. PTX, forskolin, ISO, and norepinephrine (NE) were purchased from Sigma, St. Louis, Mo. Rp-cAMPS was purchased from Biolog Life Science Institute, La Jolla, Calif.
Statistics
Data reported are meanϮSEM. Statistical comparisons were made by Student t test or paired t test when appropriate. Two-factor ANOVA was used to analyze the overall drug dose response. The significance between groups is analyzed by Bonferroni. A P value of Ͻ0.05 was considered to be statistically significant.
Results
Enhancement of Baseline Contractility of TG4 Ventricular Myocytes
In single ventricular myocytes isolated from TG4 or WT mice superfused with normal HEPES buffer solution with 1.0 mmol/L Ca 2ϩ , basal contractility was measured in the absence of any ␤AR agonists. Figure 1 shows that baseline contraction amplitude of TG4 cells was enhanced by 3.2-fold relative to myocytes isolated from WT mice. The enhanced baseline contractility was markedly reduced by ICI (5ϫ10 Ϫ7 mol/L), a ␤ 2 AR inverse agonist (a class of receptor ligands that preferentially bind to inactive receptor, therefore driving the equilibrium between R and R* to the inactive conformation R), whereas ICI alone had no significant effect on WT cell basal contraction ( Figure 1 ). However, there was no significant difference in the resting cell length between these 2 groups (144.5Ϯ5.6 m, nϭ28 for TG4 versus 141.0Ϯ4.18 m, nϭ22 for WT), consistent with the previous observations that the heart size is not changed in this transgenic model. 1 
␤ 2 AR Agonists Fail to Increase Contractility of Either TG4 or WT Ventricular Myocytes
Despite the overwhelming expression (Ϸ200-fold of WT) of ␤ 2 ARs in TG4 myocytes, 1 the selective ␤ 2 AR agonist zinterol, even at a maximal concentration (10 Ϫ5 mol/L), was unable to further augment contraction amplitude (Figure 2A ) or the [Ca 2ϩ ] i transient (not shown). The inability of ␤ 2 AR stimulation to further increase contraction amplitude in TG4 myocytes might suggest that the ␤ 2 AR signaling to augment cell contractility in TG4 cells is already at the maximal level in the absence of agonist so that ␤ 2 AR agonists would not be expected to further increase the contraction amplitude in these cells, as proposed previously. 1, 7 Alternatively, the unresponsiveness of TG4 cells might be due to some compensatory alterations, eg, a reduction in G s -adenylyl cyclase signaling, or to a defect in excitation-contraction coupling machinery in these transgenic mice. The adenylyl cyclase activator forskolin was used to test these possibilities. If the mol/L). The baseline contraction of TG4 myocytes (nϭ22 cells from 8 hearts) was significantly greater than that of WT myocytes (nϭ28 from 8 hearts). *PϽ0.01. However, in the presence of the inverse ␤ 2 AR agonist ICI (5ϫ10 Ϫ7 mol/L), there was no significant difference between these 2 groups (nϭ9 cells for both groups).
contractility in TG4 heart cells were saturated at baseline, no positive inotropic effect would be observed after forskolin treatment. To the contrary, Figure 2B illustrates that forskolin (10 Ϫ6 mol/L) markedly and reversibly enhanced contraction amplitude in a representative TG4 ventricular myocyte. On average, forskolin increased TG4 cellular contraction by 2.4-fold (from 6.1Ϯ1.0% to 14.4Ϯ1.0% of resting cell length, nϭ5 cells from 3 hearts; PϽ0.01). This result indicates that both the excitation-contraction machinery and the ␤AR signaling cascade downstream of the cyclase remain intact and are not saturated at baseline in TG4 mice. Therefore, we hypothesized that the unresponsiveness of TG4 ventricular myocytes to ␤ 2 AR stimulation likely results from an impairment within the proximal ␤ 2 AR signaling cascade.
To identify possible alterations of cardiac ␤ 2 AR signaling in TG4 mice, we next examined the effects of ␤ 2 AR stimulation in WT heart cells. Surprisingly, ␤ 2 AR stimulation by the mixed ␤AR agonist ISO (10 Ϫ6 mol/L) plus the ␤ 1 AR blocker CGP was also unable to augment contraction amplitude in WT mouse ventricular myocytes (Figure 3 ). In contrast, the mixed ␤AR stimulation by ISO alone or ␤ 1 AR stimulation by ISO plus the ␤ 2 AR blocker ICI markedly enhanced contraction amplitude in these WT myocytes (Figure 3) , consistent with previous in vivo observations that ISO in WT mice enhances cardiac performance. 1, 7, 21 Thus, the positive inotropic effect of ISO in WT cardiac myocytes or in vivo 1, 7, 21 is largely, if not exclusively, mediated by ␤ 1 AR subtype stimulation. Furthermore, as previously shown, 8 the ␤ 1 AR agonist NE plus the ␣ 1 -adrenergic blocker prazosin (10 Ϫ6 mol/L) produces a marked increase in contraction amplitude in these cells ( Figure 4D ). Again, the ␤ 2 AR selective agonist zinterol at any concentration tested up to 10 Ϫ5 mol/L failed to enhance contraction amplitude in WT mouse cardiomyocytes ( Figure 5A ), despite the fact that ␤ 2 ARs constitute about 24% of the total ␤ARs in WT mouse heart. 1 Taken together, the results so far indicate that ␤ 2 AR stimulation induced by either zinterol or by ISO plus ␤ 1 AR blockade was unable to augment contraction in either WT or TG4 mouse cardiomyocytes, whereas ␤ 1 AR agonists or adenylyl cyclase activators potently augmented the contraction amplitude in these cells. The next question, then, is why ␤ 2 AR stimulation cannot increase mouse cardiac contractility.
Rescue of Contractile and [Ca 2؉ ] i Responses to ␤ 2 AR Stimulation by PTX Treatment
Because reconstituted ␤ARs can couple to both G s and G i in artificial systems 22, 23 and in rat ventricular myocytes, PTX treatment selectively potentiates the ␤ 2 AR-mediated contractile response, 10, 11, 24 we hypothesized that a dual coupling of ␤ 2 AR to an inhibitory G protein in addition to a G s protein might also exist in intact mouse ventricular myocytes and negate the contractile response mediated by the coupling to a G s protein. To test this hypothesis, cells were incubated with PTX to abrogate G i /G o function via ADP ribosylation. Indeed, PTX pretreatment unmasked a potent positive inotropic effect after ␤ 2 AR stimulation in both TG4 and WT heart cells, as shown in Figure 4A and 4B, in a representative PTX-treated TG4 and WT ventricular myocyte, respectively. The zinterolinduced (10 Ϫ6 mol/L) increase in contraction amplitude was completely abolished by the specific ␤ 2 AR antagonist ICI (10 Ϫ7 mol/L). In contrast, the ␤ 1 AR antagonist CGP (10 Ϫ8 mol/L) could not reverse the positive inotropic effect of zinterol ( Figure 4C ) but completely blocked the increase in contraction induced by the ␤ 1 AR agonist NE (10 Ϫ7 mol/L) ( Figure 4D ). These results indicate that the PTX-rescued contractile response to zinterol is mediated by ␤ 2 AR stimulation. The average dose response of contraction amplitude to the ␤ 2 AR agonist zinterol is shown in Figure 5A and 5B for WT and TG4 cells, respectively. It is noteworthy that similar maximal contraction amplitude (Ϸ15% of resting cell length) is obtained after zinterol in both PTX-treated WT and TG4 cells. Also note that the dose-response curve for PTX-treated TG4 cells is shifted leftward relative to that for WT cells (EC 50 is Ϸ1.5ϫ10 Ϫ8 and 10 Ϫ7 mol/L for TG4 and WT groups, respectively), consistent with the greater ␤ 2 AR density in TG4 cells. In addition, Figure 6 shows that the positive inotropic effect of zinterol in both PTX-treated TG4 and WT cells was accompanied by an increase in the [Ca 2ϩ ] i transient as indexed by the increase in the fluorescence signal of the Ca 2ϩ -sensitive probe Fluo-3. Thus, the full efficacy of ␤ 2 AR stimulation is revealed in TG4 as well as in WT mouse cardiac cells only if cells were pretreated with PTX to eliminate the G i -mediated inhibitory signaling.
Rp-cAMPS Reversed the PTX-Rescued I Ca Response to ␤ 2 AR Stimulation
Because I Ca is the key factor of the ␤ 2 AR-mediated positive inotropic effect in rat and canine myocytes, 10 -12,14 we next measured the I Ca response of mouse cardiomyocytes to ␤ 2 AR stimulation. Similar to the contractile response, in the absence of PTX treatment, the ␤ 2 AR agonist zinterol (10 Ϫ5 mol/L) could not increase I Ca in WT or TG4 myocytes (data not shown). However, in PTX-treated cells, zinterol significantly enhanced the current amplitude in both WT and TG4 mice ( Figure 7 , left panels). The PTX-restored stimulatory effect of zinterol on I Ca was completely abolished by a specific cAMP-dependent protein kinase A (PKA) inhibitor, an inhibitory cAMP analog Rp-cAMPS ( Figure 7 , right panels), consistent with previous observations in other species. 11 Similar results were obtained from the other 4 WT and TG myocytes. These results suggest that the PTX-rescued murine cardiac ␤ 2 AR function is mediated by a cAMP-dependent signaling pathway.
␤ 2 AR Stimulation Selectively Increases G i Activation
The PTX sensitivity of the ␤ 2 AR effect in murine ( Figure 5 ) and rat hearts 10, 11, 24 suggest that cardiac ␤ 2 AR couples to G i proteins. However, these results neither prove a direct interaction of ␤ 2 AR and G i proteins nor identify which specific G proteins couple to ␤ 2 AR. Theoretically, the effect of PTX could be the consequence of disruption of tonic inhibitory actions of G i proteins. To determine the interaction of ␤ 2 AR and G i proteins directly and to identify which specific PTX-sensitive G proteins are involved, we measured the G protein activation by photoaffinity labeling ␣ subunits of G proteins with the photoreactive GTP analog [␥-
32 P]GTPAzA. 17 As the binding of an agonist to G protein-coupled receptors increases the rate of exchange of GTP for GDP on G protein ␣ subunits (see Reference 25 for a review), the magnitude to which [␥-32 P]GTP-AzA incorporates into ␣ subunits of G proteins affords a direct assessment of G protein activation in response to receptor stimulation. Subse- quent precipitation with specific antisera was carried out to determine which specific G protein(s) was activated during ␤ 2 AR stimulation. As expected, the incorporation of [␥-32 P]GTP-AzA into ␣ subunits of G s was clearly increased in WT mouse cardiac membranes after ␤ 2 AR stimulation by zinterol. On average, the signal was enhanced by 1.5-fold (157.66Ϯ21.15% of control, nϭ7; PϽ0.05) in response to zinterol. Meanwhile, the ␤ 2 AR agonist zinterol increased the incorporation of [␥-
32 P]GTP-AzA into the ␣ subunits of G i3 and G i2 ( Figure 8A  through 8D) , without affecting the incorporation into G o or G i1 proteins (data not shown). On average, zinterol (10 Ϫ5 mol/L) increased the incorporation of [␥-
32 P]GTP-AzA into ␣ subunits of G i2 and G i3 to 146.3Ϯ8.8% of control (PϽ0.01, nϭ12) and 148.9Ϯ5.6% of control (PϽ0.01, n ϭ13), respectively, in TG4 cardiomyocytes ( Figure 9A ). Similar results were obtained from WT mouse myocardium ( Figure 9B ). The magnitude of the ␤ 2 AR-induced increases in the ␣ subunits of G i3 and G i2 photolabeling is similar to that induced by the muscarinic acetylcholine receptor agonist carbachol (10 Ϫ5 mol/L) ( Figures 8A and 9B) . The stimulatory effect of the ␤ 2 AR agonist was specifically and significantly abolished by the ␤ 2 AR antagonist ICI ( Figures 8C, 8D , and 9A). Furthermore, the nonselective ␤AR agonist ISO also clearly enhanced the incorporation of [␥-
32 P]GTP-AzA into ␣ subunits of both G i2 and G i3 ( Figures 8E and 9A ), and this activation was specifically abolished by the ␤ 2 AR antagonist ICI but not by the selective ␤ 1 AR antagonist CGP (Figures 8E and 9A) . Similarly, the ␤ 1 AR agonist NE (10 Ϫ6 mol/L) had no significant effects on G i activation ( Figure 9B) . Thus, the G i coupling is specific for ␤ 2 AR in both WT and TG4 myocardium. Finally, the ␤ 2 AR-stimulated G i activation was prevented by PTX treatment in both TG4 and WT mice ( Figures  8F and 9B ). Taken together, the present biochemical data, in conjunction with the physiological data described above, provide direct and compelling evidence that ␤ 2 ARs but not ␤ 1 ARs in native myocardium couple to PTX-sensitive G proteins G i2 and G i3 .
Discussion
Concurrent Coupling of ␤ 2 AR to G i Proteins Negates the ␤ 2 AR-G s -Mediated Contractile Response
Using a photoaffinity labeling technique in conjunction with specific antibodies of different G proteins, we found that ␤ 2 AR stimulation increases activation of G i proteins G i2 and G i3 (Figures 8 and 9 ), in a PTX-and ICI-sensitive manner, in addition to activation of G s . These data provide the first direct biochemical evidence that ␤ 2 ARs in the native cellular environments can interact with PTX-sensitive G proteins, specifically, G i2 and G i3 . Physiological data showed that the concurrent coupling to G i proteins completely negates the ␤ 2 AR-G s -mediated contractile, [Ca 2ϩ ] i , and I Ca responses. As a result, ␤ 2 ARs in murine hearts appear to be at an apparently dormant state in terms of these cardiac responses. More importantly, the cardiac ␤ 2 AR function was fully restored after inhibiting G i by PTX, as manifested by the robust effects of the ␤ 2 AR agonist zinterol to augment [Ca 2ϩ ] i , I Ca , and contraction amplitudes in both PTX-treated TG4 and WT cells. An examination of the dose responses of contraction with and without PTX treatment in both TG4 and WT myocytes further reveals that the ␤ 2 AR-G i coupling completely negates the G s -mediated contractile response over a wide range of receptor densities and agonist concentrations. Thus, the concurrent coupling of ␤ 2 ARs to G i proteins provides an explanation for the "mysterious" loss of agonistinduced ␤ 2 AR contractile response in TG4 and WT murine hearts. 1, 7, 21 In addition, similar reasoning may also be applicable to explain the unresponsiveness of cardiac contractility to ␤ 2 AR stimulation in the ␤ 1 AR "knockout" mouse model, 9 as well as in myocardium of other mammalian species (eg, guinea pig), in which ␤ 2 ARs are present but nonfunctional in terms of cardiac contractile modulation. 26, 27 
PTX-Rescued Murine Cardiac ␤ 2 AR Function Requires cAMP-Dependent PKA Activation
There is plenty of evidence indicating a coupling of ␤ 2 AR to adenylyl cyclase to increase cAMP. 13, 28, 29 In the present study and previous studies, the specific cAMP inhibitory analog Rp-cAMPS prevented the ␤ 2 AR-stimulated increase in I Ca in PTX-treated TG4 and WT myocytes ( Figure 7 ) and in rat heart cells (with or without PTX), 11 indicating that cAMPdependent PKA activation is obligatory for mammalian ␤ 2 AR cardiac responses. Thus, the positive inotropic effects induced by both ␤ 1 AR and ␤ 2 AR subtypes are mediated by cAMP-PKA signaling pathways. 11, 30 However, ␤ 1 AR does not behave the same way as ␤ 2 AR with respect to coupling to G i proteins under our experimental conditions (Figures 8 and  9 ). Similarly, our previous studies have shown that in rat ventricular myocytes, PTX pretreatment selectively enhances the positive inotropic effect of ␤ 2 AR stimulation, 10, 11, 24 suggesting that PTX-sensitive G i -proteins specifically interact with ␤ 2 AR but not ␤ 1 AR. Therefore, the essential difference between ␤ 1 AR-and ␤ 2 AR-mediated cardiac responses is largely due to the additional coupling of ␤ 2 AR to G i proteins, which provides a negative feedback to the ␤ 2 AR-stimulated cAMP-dependent signaling.
Dual Coupling of ␤ 2 AR to G i Proteins Mediates the Difference Between ␤AR Subtypes and the Species-Dependent Diversity in Cardiac ␤ 2 AR Responses
The coupling of ␤ 2 AR to G i proteins is not unique to native murine ␤ 2 AR or to human ␤ 2 AR surrogated in mouse cardiac myocytes. Our previous studies have shown that although stimulation of both ␤ 1 AR and ␤ 2 AR increases the contraction amplitude in rat and canine ventricular myocytes, numerous 32 P]GTPAzA. Photolabeled ␣ subunits were subsequently incubated with G␣ i3 or G␣ i2 polyclonal antibodies (anti-rabbit) and immunoprecipitated. Precipitated proteins were subjected to SDS-PAGE. Activated G protein ␣ subunits were visualized by autoradiography. A, Stimulatory effect of zinterol (Z) at 10 Ϫ5 mol/L and the acetylcholine receptor agonist carbachol (cch, 10 Ϫ5 mol/L) on the incorporation of [ 32 P]GTP-AzA into ␣ subunits of G i3 . B, Photolabeling of ␣ subunits of G i3 in the absence and presence of zinterol (Z). The right 2 lanes show that control peptides of G i3 antibody at a concentration of 5-fold greater than that of G i3 antibody completely abolished the G i3 antibody-induced protein precipitation. C and D, Photolabeling of ␣ subunits of G i3 and G i2 in response to zinterol (Z) in the absence or presence of the ␤ 2 AR blocker ICI 118,551 (I) at 10 Ϫ6 mol/L. E, Stimulatory effect of isoproterenol (IS) at 10 Ϫ6 mol/L in the presence or absence of a selective ␤ 2 AR antagonist ICI (10 Ϫ6 mol/L) or ␤ 1 AR blocker CGP (10 Ϫ6 mol/L) on the photolabeling of ␣ subunits of G i2 . F, PTX treatment prevents the stimulatory effect of zinterol (Z) on G i2 activation. In addition, in all experiments, preimmune antisera did not precipitate any photolabeled proteins, indicating that precipitation with the antisera used in the present study was specific (data not shown). Molecular masses (kDa) of standard proteins are shown on the left. differences have been noted. Specifically, the ␤ 2 AR-but not the ␤ 1 AR-stimulated positive inotropic effect and increase in cytosolic Ca 2ϩ transient are dissociated from cAMP production and occur without increasing phosphorylation of cytoplasmic proteins, eg, the sarcoplasmic reticulum membrane protein phospholamban. 13, 14 Interestingly, in rat myocytes, PTX treatment not only potentiates the positive inotropic effect of ␤ 2 AR stimulation, 10 it also largely reverses the differences between ␤ 1 AR and ␤ 2 AR, 11 indicating ␤ 2 AR-activated G i proteins play a key role in the differential cardiac response to ␤ 2 AR versus ␤ 1 AR subtype stimulation. A similar potentiating effect of PTX on ␤ 2 AR contractile response has also been observed in normal canine ventricular myocytes (Zhou et al, unpublished data, 1998) . These results reinforce the idea that the concurrent coupling of ␤ 2 AR to functionally opposing G proteins is a universal phenomenon in mammalian hearts.
In murine cardiomyocytes, PTX permits a de novo contractile response ( Figure 5 ). In contrast to mice, PTX pretreatment only augments an already extant positive ␤ 2 AR contractile response in other species examined. 10, 11, 24 This diversity in cardiac ␤ 2 AR stimulation among species or within species under different circumstances may be largely accounted for on the basis of quantitative differences in the extent of ␤ 2 AR-G i coupling. For example, the ␤ 2 AR-G i coupling would be expected to be extremely robust in mouse heart, as manifested by the absence of a ␤ 2 AR-mediated positive inotropic effect without PTX pretreatment. In rat, an augmentation of the extent of ␤ 2 AR coupling to G i proteins during development could explain the greater sensitivity of neonatal than that of adult heart cells to ␤ 2 AR activation in the absence of PTX. 15 The difference between ␤ 1 AR and ␤ 2 AR in their G protein coupling profiles may also provide new insight for understanding the role of ␤AR subtypes in health and diseased mammalian heart (References 12 through 15; also see subsequent sections).
Peculiar Features of TG4 Myocytes
The results of the present study show that TG4 mouse ventricular myocytes overexpressing human ␤ 2 AR exhibit a markedly enhanced baseline contractility, which can be reversed by the inverse ␤ 2 AR agonist ICI (Figure 1 ). Because our experiments were conducted in superfused single, isolated ventricular myocytes, possible endogenous catecholamine contamination, which might complicate the interpretation of observations of previous studies in vivo and in isolated atria, 1, 7, 21 can be completely ruled out. Thus, the results of the present study confirm and extend previous studies and provide evidence at the single cell level for the functional existence of spontaneous active ␤ 2 ARs in TG4 mice. Conceptually, a small fraction of receptors undergoes spontaneous transition to an active state (R*) at any time, even in the absence of agonist. 7 The Ϸ200-fold overexpression of the ␤ 2 AR in TG4 hearts results in more receptors in the R* state, which constitutively increase basal adenylyl cyclase activity 1, 7 and baseline cellular contractility (Figure 1) .
The results of the present study also show that the inability of ␤ 2 AR agonists to augment the contractility of TG4 cardiomyocytes cannot be explained by a saturation of contractility at baseline. The reason for this is that the adenylyl cyclase activator forskolin can further increase contraction amplitude over the enhanced basal contraction, indicating that the cAMP-PKA signaling is still capable of modulating the contractility of TG4 heart cells. More importantly, the lack of ␤ 2 AR positive inotropic effect was also observed in WT mouse myocytes, indicating that the null contractile response to ␤ 2 AR agonists has nothing to do with the receptor overexpression or chronic spontaneous ␤ 2 AR activation in the transgenic model, but it is a fundamental property of ␤ 2 AR signaling in murine heart. In addition, the results of the present study indicate that the ␤ 2 AR-G i coupling is retained over a wide range of ␤ 2 AR densities and agonist concentrations.
Another peculiar feature of TG4 hearts is an absence of contractile response to ␤ 1 AR stimulation, as manifested by the inability of ␤ 1 AR stimulation by NE or ISO in vivo 7, 21 or the inability of ISO plus the ␤ 2 AR blocker ICI to increase cardiac contractility in single isolated myocytes (data not shown). Although PTX treatment fully rescued the ␤ 2 AR responsiveness in TG4 cardiomyocytes, it was not able to rescue the lost cardiac response to ␤ 1 AR stimulation in these transgenic mice (data not shown). This is consistent with the observation that ␤ 1 AR does not couple to G i proteins ( Figures  8 and 9 ). These results suggest that a different mechanism might be involved in the subsensitivity of TG4 hearts to ␤ 1 AR stimulation (eg, desensitization of the receptor via an enhanced basal PKA-dependent receptor phosphorylation or by the ␤-adrenergic receptor kinase ␤ARK 2,31,32 ).
Do Spontaneous Active ␤ 2 ARs Differ From Ligand-Stimulated ␤ 2 ARs?
According to the current "two-state" model of receptor theory, 7 receptors exist in equilibrium of an inactive state (R) and an active state (R*) in terms of the ability to interact with G proteins. This model predicts that spontaneous active receptors should be identical to ligand-stimulated active receptor species (LR*), given that there is a sole active state. The results of the present study, however, provide several lines of evidence to suggest that spontaneously activated ␤ 2 AR may differ from the ligand-stimulated ␤ 2 AR. First, whereas spontaneous active ␤ 2 ARs in TG4 heart, presumably only a small fraction of total receptor population, 1 increased the cell contractility by about 3-fold, ␤ 2 AR agonists, at maximal concentrations that would be expected to occupy a large quantity of the excessive ␤ 2 ARs in TG4 cells, were unable to further increase contraction amplitude, even though the cell contractility and ␤AR-cAMP signaling are not saturated. Second, PTX treatment only slightly potentiated the basal contractility (in TG4 cells only) but had a disproportionally large potentiating effect on the agonist-stimulated contractile response in both TG4 and WT heart cells ( Figure  5 ), suggesting that the spontaneously activated ␤ 2 AR, unlike the agonist activated ␤ 2 AR, only weakly couples or does not couple to G i proteins. In this respect, recent studies in transgenic mice with high or medium overexpression of cardiac ␤ 2 AR have demonstrated that spontaneously activated ␤ 2 ARs coprecipitate with G s but not G i /G o proteins in the absence of agonist. 33 Our preliminary data have also consis-tently shown that the ␤ 2 AR inverse agonist ICI (5ϫ10 Ϫ7 mol/L) reduced the basal incorporation of [␥-
32 P]GTP-Aza into ␣ subunits of G s but not G i proteins in TG4 mice (Avdonin et al, unpublished data, 1998). Taken together, we suggest that spontaneous active ␤ 2 ARs are predominantly coupled to G s with little or no coupling to G i proteins, whereas the ligand-activated ␤ 2 ARs couple to both G s and G i proteins. The distinct difference between the spontaneous and ligand-induced active ␤ 2 ARs demonstrated in the present study and in previous studies of murine myocardium requires a reformulation of the current model 7 to describe receptor-G protein coupling in the physiological context.
Implications of ␤ 2 AR-G i Coupling in the Heart
In addition to modulating the ␤ 2 AR-G s -mediated enhancement in cardiac contractility, the ␤ 2 AR-stimulated G i activation might have chronic effects, eg, cellular metabolism or excitability or cell growth, which requires additional investigations. In this regard, it is intriguing that ␤ 2 AR overexpression in TG4 mice is not associated with a cardiac or cellular hypertrophy 1 and exhibits no change in the size of single isolated cardiomyocytes (as shown in the present study), whereas a genetic manipulation of G s -cAMP signaling system 3 or chronic ␤AR stimulation by agonists 34, 35 is often associated with cardiac hypertrophy or heart failure. Thus, we speculate that ␤AR subtypes may differentially regulate cell growth as a result of the additional ␤ 2 AR-G i coupling. In addition, it has been shown that inhibition of G i function by PTX treatment increases the occurrence of spontaneous cell contractions in rat ventricular myocytes 10 and arrhythmia in intact rats (Eschenhagen et al, unpublished data, 1998 ) during ␤AR agonist stimulation. Thus, an activation of the ␤ 2 ARcoupled G i proteins may have some cardiac protective functions.
The demonstration that ␤ 2 AR couples to G s and G i also provides new insights for the pathogenesis of heart failure. It is generally acknowledged that heart failure in human and animal models is characterized by a deterioration in cardiac contractility and a reduced catecholamine responsiveness, which are associated with an increase in G i mRNA levels, 36 G i activity as indicated by PTX-induced ribosylation 37 or G i protein amount in human 38 or in animal models 39 and an increase in the ratio of ␤ 2 AR to ␤ 1 AR as a result of a selective downregulation of ␤ 1 ARs. 40 -42 It has been proposed that the upregulation of G i proteins may contribute to the suppressed ␤AR, particularly ␤ 1 AR, contractile response in the failing hearts. 36 -39 However, this hypothesis has not been directly examined, because most previous studies failed to determine whether the increased G i activity differentially affected ␤AR subtype signaling. On the basis of biochemical and physiological evidence for a coupling of ␤ 2 AR to G i proteins (References 10 and 11 and the present study), it is possible that, on one hand, the upregulation of G i proteins could protect the diseased heart from Ca 2ϩ overloading and arrhythmia; and on the other hand, the upregulated G i signaling in failing hearts could offset or mask the ␤ 2 AR-stimulated positive inotropic effect, resulting in an attenuation or loss of the overall ␤AR-mediated inotropic response. Additional studies are required to test these provocative hypotheses.
In summary, we demonstrate that ␤ 2 AR stimulation cannot augment contractile function in isolated single WT or receptor overexpression transgenic (TG4) cardiac myocytes, although spontaneous ␤ 2 AR activation enhances the baseline contractility of TG4 myocytes. We also provide the first biochemical evidence that in murine cardiac myocytes, ␤ 2 AR is dually coupled to inhibitory G proteins G i2 and G i3 in addition to G s . PTX treatment permits ␤ 2 AR stimulation to induce a robust augmentation in contraction, associated with an increase in I Ca and [Ca 2ϩ ] i transient. The PTX-restored cardiac ␤ 2 AR response can be reversed by the inhibitory cAMP analog Rp-cAMPS. Thus, the ␤ 2 AR-coupled G i pathway exerts a strong negative feedback to the ␤ 2 AR-mediated, cAMP-dependent cardiac contractile and [Ca 2ϩ ] i transient and I Ca responses. These findings may have important implications not only for understanding signaling mechanisms and functionality of cardiac ␤AR subtypes but also for devising future strategies for the treatment of human heart failure via genetic therapy.
